KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Assets Average (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Assets Average for 15 consecutive years, with $2.1 billion as the latest value for Q1 2025.

  • On a quarterly basis, Assets Average changed N/A to $2.1 billion in Q1 2025 year-over-year; TTM through Mar 2025 was $2.1 billion, a N/A change, with the full-year FY2024 number at $1.9 billion, up 6.21% from a year prior.
  • Assets Average was $2.1 billion for Q1 2025 at Halozyme Therapeutics, up from $2.1 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $2.1 billion in Q1 2025 to a low of $773.3 million in Q1 2021.
  • A 5-year average of $1.5 billion and a median of $1.8 billion in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 110.39% in 2021, then dropped 2.16% in 2023.
  • Halozyme Therapeutics' Assets Average stood at $1.1 billion in 2021, then soared by 61.85% to $1.9 billion in 2022, then fell by 2.16% to $1.8 billion in 2023, then rose by 15.32% to $2.1 billion in 2024, then increased by 1.88% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for HALO's Assets Average are $2.1 billion (Q1 2025), $2.1 billion (Q4 2024), and $1.8 billion (Q4 2023).